Technical Analysis for IMGN - ImmunoGen, Inc.

Grade Last Price % Change Price Change
B 16.00 3.90% 0.60
IMGN closed up 3.9 percent on Thursday, September 28, 2023, on 73 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
20 DMA Resistance Bearish 3.90%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.90%
Stochastic Buy Signal Bullish 6.88%
Lower Bollinger Band Walk Weakness 6.88%
Gapped Up Strength 6.88%
Oversold Stochastic Weakness 6.88%
NR7 Range Contraction 9.36%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR about 10 hours ago
Up 3% about 11 hours ago
10 DMA Support about 12 hours ago
Up 2% about 12 hours ago
Up 1% about 13 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


ImmunoGen, Inc. Description

ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Solid Tumors Drugs Monoclonal Antibodies Breast Cancer Lymphoma Non Small Cell Lung Cancer Ovarian Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Medical Research Multiple Myeloma Antibody Drug Conjugate Her2 Chronic Lymphocytic Leukemia Hematological Malignancies Lymphocytic Leukemia Clinical Trial Product Cancer Therapeutics Acute Lymphoblastic Leukemia Immunogen Metastatic Breast Cancer B Cell Acute Lymphoblastic Leukemia Mesothelin

Is IMGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 20.69
52 Week Low 3.61
Average Volume 4,192,736
200-Day Moving Average 10.48
50-Day Moving Average 16.08
20-Day Moving Average 15.46
10-Day Moving Average 15.24
Average True Range 0.62
RSI (14) 54.95
ADX 19.33
+DI 25.82
-DI 25.47
Chandelier Exit (Long, 3 ATRs) 14.57
Chandelier Exit (Short, 3 ATRs) 16.27
Upper Bollinger Bands 16.31
Lower Bollinger Band 14.61
Percent B (%b) 0.82
BandWidth 10.94
MACD Line -0.22
MACD Signal Line -0.28
MACD Histogram 0.0604
Fundamentals Value
Market Cap 3 Billion
Num Shares 188 Million
EPS -1.19
Price-to-Earnings (P/E) Ratio -13.45
Price-to-Sales 10.59
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.23
Resistance 3 (R3) 17.10 16.57 17.03
Resistance 2 (R2) 16.57 16.25 16.63 16.96
Resistance 1 (R1) 16.28 16.06 16.43 16.41 16.89
Pivot Point 15.75 15.75 15.82 15.81 15.75
Support 1 (S1) 15.46 15.43 15.61 15.59 15.11
Support 2 (S2) 14.93 15.24 14.99 15.04
Support 3 (S3) 14.64 14.93 14.98
Support 4 (S4) 14.77